4.7 Article

Multivitamins in the Prevention of Cardiovascular Disease in Men The Physicians' Health Study II Randomized Controlled Trial

Journal

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 308, Issue 17, Pages 1751-1760

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2012.14805

Keywords

-

Funding

  1. NIH (Bethesda, Maryland) [CA 097193, CA 34944, CA 40360, HL 26490, HL 34595]
  2. BASF Corporation (Florham Park, New Jersey)
  3. Tomato Products Wellness Council
  4. National Institutes of Health (NIH)
  5. Cambridge Theranostics Ltd.
  6. Harvard University (Clinical Nutrition Research Center)
  7. DSM Nutritional Products Inc
  8. nonprofit Aurora Foundation
  9. Bristol-Meyers Squibb
  10. AstraZeneca
  11. Novartis
  12. Veterans Administration
  13. BASF Corporation

Ask authors/readers for more resources

Context Although multivitamins are used to prevent vitamin and mineral deficiency, there is a perception that multivitamins may prevent cardiovascular disease (CVD). Observational studies have shown inconsistent associations between regular multivitamin use and CVD, with no long-term clinical trials of multivitamin use. Objective To determine whether long-term multivitamin supplementation decreases the risk of major cardiovascular events among men. Design, Setting, and Participants The Physicians' Health Study II, a randomized, double-blind, placebo-controlled trial of a common daily multivitamin, began in 1997 with continued treatment and follow-up through June 1, 2011. A total of 14 641 male US physicians initially aged 50 years or older (mean, 64.3 [SD, 9.2] years), including 754 men with a history of CVD at randomization, were enrolled. Intervention Daily multivitamin or placebo. Main Outcome Measures Composite end point of major cardiovascular events, including nonfatal myocardial infarction (MI), nonfatal stroke, and CVD mortality. Secondary outcomes included MI and stroke individually. Results During a median follow-up of 11.2 (interquartile range, 10.7-13.3) years, there were 1732 confirmed major cardiovascular events. Compared with placebo, there was no significant effect of a daily multivitamin on major cardiovascular events (11.0 and 10.8 events per 1000 person-years for multivitamin vs placebo, respectively; hazard ratio [HR], 1.01; 95% CI, 0.91-1.10; P=.91). Further, a daily multivitamin had no effect on total MI (3.9 and 4.2 events per 1000 person-years; HR, 0.93; 95% CI, 0.80-1.09; P=.39), total stroke (4.1 and 3.9 events per 1000 person-years; HR, 1.06; 95% CI, 0.91-1.23; P=.48), or CVD mortality (5.0 and 5.1 events per 1000 person-years; HR, 0.95; 95% CI, 0.83-1.09; P=.47). A daily multivitamin was also not significantly associated with total mortality (HR, 0.94; 95% CI, 0.88-1.02; P=.13). The effect of a daily multivitamin on major cardiovascular events did not differ between men with or without a baseline history of CVD (P=.62 for interaction). Conclusion Among this population of US male physicians, taking a daily multivitamin did not reduce major cardiovascular events, MI, stroke, and CVD mortality after more than a decade of treatment and follow-up.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available